EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia

Jiaxu Zhou, Zhongtang Li iD, Xiaojiao Sun, Xiangyu Zhang, Yan He, Cheng Shi, Xiaowei Chi, Dehua Lu, Weiping Lyu, Siyu Xiu iD, Tingting Yang, Yanming Chen und 10 weitere

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19187-19203

DOI: 10.1021/acs.jmedchem.6c01512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.06.2026. Verfasst von Jiaxu Zhou und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing100191, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Proto-Oncogene Proteins, Cell Cycle Proteins, Pteridines. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Ministry of Education of the People's Republic of China, China Postdoctoral Science Foundation, Science and Technology Department of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polo-like kinase 1 (PLK1) is a validated cancer therapeutic target, but ATP-competitive PLK1 inhibitors have been limited by dose-limiting toxicities. Here, we designed covalent inhibitors that specifically engage the noncatalytic Cys67 residue of the ATP domain. Rational optimization of the warhead and core scaffold led to B9 as a highly potent lead candidate. B9 exhibited low nanomolar enzymatic inhibition and exceptional cellular potency (IC50 = 0.4 nM in K562 leukemia cells), representing a >150-fold improvement over the reversible reference compound BI2536 (61 nM). B9 also showed favorable overall selectivity against nonrelated kinases. Remarkably, B9 achieved 77.6% oral bioavailability in mice. In an orthotopic K562 leukemia xenograft model, oral administration of B9 significantly suppressed the bioluminescence of leukemia burden and extended survival rates to 100% over 42 days without observable toxicity. These findings underscore the potential of B9 as a safe, orally bioavailable, and highly potent PLK1 inhibitor for preclinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesProto-Oncogene ProteinsCell Cycle ProteinsPteridinesAntineoplastic AgentsProtein Kinase InhibitorsDrug DesignLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansPolo-Like Kinase 1AnimalsMiceAdministration, OralStructure-Activity RelationshipBiological AvailabilityXenograft Model Antitumor AssaysK562 Cells

Substanzen

Protein Serine-Threonine KinasesPolo-Like Kinase 1Proto-Oncogene ProteinsCell Cycle ProteinsPteridinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing100191, China.
  • Department of Surgical Oncology Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing100045, China.
  • College of Pharmacy, Xinjiang Medical University, Urumqi830011, China.
  • Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei230009, China.
  • Key Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education; School of Pharmacy, Shihezi University, Shihezi832002, China.
  • Beijing Key Laboratory of AI-Driven Drug Discovery and Development, Peking University, Beijing100191, China.

ORCID-Profile: Zhongtang Li, Siyu Xiu, Qi Li, Liangren Zhang, Zhenming Liu

Förderung

  • Ministry of Education of the People's Republic of China
  • China Postdoctoral Science Foundation
  • Science and Technology Department of Zhejiang Province
  • Xinjiang Key Laboratory of Natural Medicine Active Components and Drug Release Technology, Xinjiang Medical University
  • National Natural Science Foundation of China (NSFC)
  • Beijing Municipal Natural Science Foundation

Zitieren

APA

Zhou, J., Li, Z., Sun, X., Zhang, X., He, Y., Shi, C., Chi, X., Lu, D., Lyu, W., Xiu, S., Yang, T., Chen, Y., Wang, Z., Li, Q., Zheng, R., Du, J., Lin, Y., Yan, J., Li, T., …, & Liu, Z. (2026). Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia. Journal of Medicinal Chemistry, 69(15), 19187-19203. https://doi.org/10.1021/acs.jmedchem.6c01512

Vancouver

Zhou J, Li Z, Sun X, Zhang X, He Y, Shi C, et al. Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia. Journal of Medicinal Chemistry. 2026;69(15):19187-19203. doi:10.1021/acs.jmedchem.6c01512

BibTeX
@article{Zhou2026,
  author = {Zhou, Jiaxu and Li, Zhongtang and Sun, Xiaojiao and Zhang, Xiangyu and He, Yan and Shi, Cheng and Chi, Xiaowei and Lu, Dehua and Lyu, Weiping and Xiu, Siyu and Yang, Tingting and Chen, Yanming and Wang, Zhongwei and Li, Qi and Zheng, Ruqiu and Du, Jiarui and Lin, Yu and Yan, Jinghao and Li, Tengfei and Liao, Chenzhong and Zhang, Liangren and Liu, Zhenming},
  title = {Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {19187--19203},
  doi = {10.1021/acs.jmedchem.6c01512}
}
Kostenlos starten →